Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Items 301–400 of 729

Current approaches to overcome the limit of TRAIL-based treatment in colorectal cancer: From fusion protein to nano-delivery platform
Chen, X., Yang, X., Chen, X., Cheng, Y., & Li, Z. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126031 · Cited by 9
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Lei, M., Overman, M. J., Yao, J. G., André, T., Lonardi, S., Lenz, H., Aglietta, M., Gelsomino, F., McDermott, R., Wong, K. Y. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63960-8 · Cited by 8
Self-citation
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
Élez, E., Siena, S., Bianchi, A. S., Ros, J., Ciardello, F., Martinelli, E., Steeghs, N., Huijberts, S. C. F. A., Cervantes, A. M. R., Roselló, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105892 · Cited by 8
Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI
Cataldi, C., Karaoğlan, B. B., Liotta, E., & Dosso, S. D. (2026) · Cancers · doi:10.3390/cancers18050852 · Cited by 10
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
DeCarli, K., Strosberg, J., & Almhanna, K. (2022) · Cancers · doi:10.3390/cancers14174201 · Cited by 8
Therapeutic Antibodies in Cancer Treatment in the UK
Eltarhoni, K., Kamel, F., Ihebunezie, K., Nisar, P. J., & Soloviev, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314589 · Cited by 8
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition
Mishima, S., Naito, Y., Akagi, K., Hayashi, N., Hirasawa, A., Hishiki, T., Igarashi, A., Ikeda, M., Kadowaki, S., Kajiyama, H., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02397-9 · Cited by 9
Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
Song, Y., Kerr, T. D., Sanders, C., Dai, L., Baxter, S. S., Somerville, B., Baugher, R. N., Mellott, S. D., Young, T. B., Lawhorn, H. E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1223915 · Cited by 8
Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons
Clerick, J., Oosterwyck, A. V., & Carton, S. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100807 · Cited by 8
Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
Gikandi, A., Chi, S. N., Yeo, K. K., O'Neill, A. F., Shulman, D. S., DuBois, S. G., & Collins, N. B. (2024) · Cancer Medicine · doi:10.1002/cam4.7154 · Cited by 7
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer
Bessudo, A., Haseeb, A., Reeves, J. A., Zhu, X., Wong, L., Giranda, V. L., Suttner, L. H., Liu, F., Chatterjee, M. S., & Sharma, S. K. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.003 · Cited by 8
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer
Saeed, A., Tabernero, J. M., Parikh, A. R., den Eynde, M. V., Karthaus, M., Gerlinger, M., Wang, Z., Wang, G., Smith, R., & Hecht, J. R. (2024) · Future Oncology · doi:10.1080/14796694.2024.2352276 · Cited by 9
Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials
Chen, K., Chen, W., Yue, R., Zhu, D., Cui, S., Zhang, X., Jin, Z., & Xiao, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1439624 · Cited by 8
The Establishment and Experimental Verification of an lncRNA-Derived CD8+ T Cell Infiltration ceRNA Network in Colorectal Cancer
Wu, Q., Zhang, Z., Ji, M., Yan, T., Jiang, Y., Chen, Y., Jiang, C., Zhang, J., Tang, D., Zhu, D., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221092218 · Cited by 8
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Meltzer, S., Negård, A., Bakke, K. M., Hamre, H. M., Kersten, C., Hofsli, E., Guren, M. G., Sørbye, H., Flatmark, K., & Ree, A. H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02004-0 · Cited by 8
The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases
Shimura, Y., Komatsu, S., Nagatani, Y., Funakoshi, Y., Sofue, K., Kido, M., Kuramitsu, K., Gon, H., Fukushima, K., Urade, T., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13746-3 · Cited by 8
Management of Older Adults With Colorectal Cancer: The Role of Geriatric Assessment
Özlük, A. A., Outlaw, D. A., Akce, M., Fowler, M. E., Hess, D. L., Giri, S., & Williams, G. R. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.10.003 · Cited by 8
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models
Luo, J., Ng, W., Liu, Y., Wang, L., Gong, C., Zhou, Y., Cheng, F., Zhu, S., & Yao, C. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03706-5 · Cited by 7
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
Ree, A. H., Høye, E., Esbensen, Y., Beitnes, A.-C. R., Negård, A., Bernklev, L., Tetlie, L. K., Fretland, Å. A., Hamre, H. M., Kersten, C., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2372886 · Cited by 7
Fruquintinib Combined With PD-1 Inhibitors for the Treatment of the Patients With Microsatellite Stability Metastatic Colorectal Cancer: Real-World Data
He, L., Cheng, X., Gu, Y., Zhou, C., Li, Q., Zhang, B., Cheng, X., & Tu, S. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.103700 · Cited by 7
Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor
Honoré, N., Laliotis, G., Aushev, V. N., Velichko, S., Palsuledesai, C. C., Dahou, H., van Marcke, C., Galot, R., Liu, M., & Machiels, J. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1309 · Cited by 7
Discordance between radiological and pathological response to neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancer: a meta-analysis
Xie, Y., Liao, L., Ding, P., & Jiang, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1680500 · Cited by 7
Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
Dong, J., Qian, Y., Zhang, G., Lu, L., Zhang, S., Ji, G., Zhao, A., & Xu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.884423 · Cited by 7
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
Luo, Y., Sun, N., & He, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01022-x · Cited by 7
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer
Janssens, K., Lambrechts, C., Geerinckx, B., de Beeck, K. O., Camp, G. V., Oliveres, H., Prenen, H., Vandamme, T., & Peeters, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01095-y · Cited by 9
Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
Zhang, Q., Li, J., Shen, L., Li, Y., & Wang, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0240 · Cited by 7
Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions
Chen, J.-T., Zhou, Y., Han, T.-R., Wei, J.-L., & Qiu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269341 · Cited by 7
Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs. chemotherapy alone in HER2(–) locally advanced gastric cancer: A propensity score-matched cohort study
Xu, G., Liu, T., Shen, J., & Guan, Q. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003028 · Cited by 7
Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers
Ozawa, R., Nishikawa, T., Yoshida, H., Shiraishi, K., Shimoi, T., Kato, T., & Yonemori, K. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e103 · Cited by 7
Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis
Huang, Z., Li, C., Huang, Y., Liang, W., & Tao, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425596 · Cited by 7
Emerging Therapies in Penile Cancer
Alencar, A. M., & Sonpavde, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910335 · Cited by 7
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
Maiorano, B. A., Parisi, A., Maiello, E., & Ciardiello, D. (2022) · Life · doi:10.3390/life12101552 · Cited by 8
Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases
Araújo, R. L. C., da Fonseca, L. G., Silva, R. O., Linhares, M. M., & Usón, P. L. S. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-616 · Cited by 7
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment
Vonica, R. C., Butucă, A., Morgovan, C., Pumnea, M., Cipăian, R. C., Frum, A., Dobrea, C. M., Vonica-Țincu, A. L., Pacnejer, A.-M., Ghibu, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040501 · Cited by 6
Surgical Outcomes in Metastatic Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer After Disease Control With Immune Checkpoint Inhibitors: A Retrospective Observational Study
Sui, Q., Liao, L., Yu, J., Zhang, L., Xiao, B.-Y., Jiang, W., Pan, Z. Z., & Ding, P. (2025) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000003845 · Cited by 6
Colorectal cancers associated with mismatch repair deficiency
Sun, M., Monahan, K. J., Moquet, J., & Barnard, S. G. R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1649565 · Cited by 6
Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment
Noorkhajavi, G., Banakholdi, A., Torabi, A., Zoghi, A., Iranijam, E., & Safarzadeh, E. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04039-8 · Cited by 6
Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Oliveres, H., Cascante, M., & Maurel, J. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102401 · Cited by 6
Correlation between mismatch repair statuses and the prognosis of stage I–IV colorectal cancer
Tong, G., Zhang, G., Hu, Y. P., Xu, X., & Wang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1278398 · Cited by 5
ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients
Puccini, A., Grillo, F., Fassan, M., Lonardi, S., Genuardi, M., Cannizzaro, R., Cavestro, G. M., Marmorino, F., Conca, V., Salvatore, L., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100044 · Cited by 6
Self-citation
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Liu, Z., Chu, H., Zhao, W., Yang, C., Liu, T., Shen, N., & Tang, Z. (2024) · Advanced Science · doi:10.1002/advs.202408899 · Cited by 6
Mouse colorectal cancer organoids: Lessons from syngeneic and orthotopic transplantation systems
Muta, Y., & Nakanishi, Y. (2025) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2025.151478 · Cited by 6
Hereditary Micro‑Satellite Instable cancers associated with Lynch Syndrome: predictive biomarkers and novel immuno-therapeutic approaches
Ponti, G., Gelsomino, F., Tomasi, A., Özben, T., Losi, L., & Manfredini, M. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2504915 · Cited by 6
MSI-H/dMMR mCRC: ICIs in the first line?
Sidaway, P. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00576-z · Cited by 6
New Opportunities for Minimizing Toxicity in Rectal Cancer Management
Couwenberg, A. M., Varvoglis, D. N., Grieb, B. C., Marijnen, C. A. M., Ciombor, K. K., & Guillem, J. G. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389558 · Cited by 6
Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature
Dibos, M., Dumoulin, J., Mogler, C., Wunderlich, S., Reichert, M., Rasch, S., Schmid, R. M., Ringelhan, M., Ehmer, U., & Lahmer, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144641 · Cited by 7
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
Krekeler, C., Wethmar, K., Mikesch, J., Kerkhoff, A., Menck, K., Lenz, G., Schildhaus, H., Wessolly, M., Hoffmann, M. W., Pascher, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512056 · Cited by 6
A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer
Okoye, C., Tran, M., Soladoye, E., Akahara, D. E., Emeasoba, C. M., Ojinna, B. T., Kelechi, A. E., Obadare, O. O., Diala, C. S., Salaudeen, B. H., et al. (2023) · Cureus · doi:10.7759/cureus.43189 · Cited by 6
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
García‐Carbonero, R., Astorga, B. G., Tocino, R. V., Toledo, D. C., Pericay, C., Montés, A. F., Falcó, E., Cordero, M. G., Zoilo, J. J. R., Alonso, V., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03309-z · Cited by 6
Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer
Aktar, S., Islam, F., Cheng, T. T., Gamage, S. M. K., Choudhury, I. N., Islam, M. S., Lu, C., Hamid, F. B., Ishida, H., Abe, I., et al. (2023) · Genes · doi:10.3390/genes14091808 · Cited by 5
Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes
Zou, D., & Xu, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-53257-z · Cited by 6
Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy
Hino, C., Lee, E. W., & Yang, G. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-105 · Cited by 6
High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT)
Ding, Y., Feng, Y. D., Ye, Y., Shen, J., Guo, C., He, X., Zhu, L., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1503517 · Cited by 5
Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer
Edin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren‐Burström, A., Guelpen, B. R. V., Ling, A., Ljuslinder, I., & Palmqvist, R. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546406 · Cited by 5
Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging
Tao, W., Zhu, J., Fu, Z., Liu, X., Tang, S., Xiang, H., & Luo, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118121 · Cited by 5
Metastatic sites and lesion numbers cooperated to predict efficacy of PD ‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer
Jiang, W., He, Y., He, W., Zhang, X., Chen, N., Li, Y., Zhong, W., Wu, G. S., Zhou, X., Hua, H., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5959 · Cited by 4
Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study
Zhang, J., Li, S., Ma, P., Zhang, J., Cao, Y., Liu, C., Zhang, X., Li, Z., Li, C., & Zhao, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-4 · Cited by 5
The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study
Xu, T., Feng, L., Zhang, W., Li, H., Ma, H., Abulimiti, M., Tan, Y., Deng, F., Huang, W., Zou, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12254-1 · Cited by 5
Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies
Kefas, J., & Flynn, M. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.67 · Cited by 6
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Shouki, B., Abdelsalam, A., Abdullah, A. S., Alshammari, K. M., Ahmed, A. M., Dawoud, E., Heinemann, V., Mohamed, A., Chehal, A. A., Mohammed, A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299324 · Cited by 5
Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials
Naleid, N., Mahipal, A., & Chakrabarti, S. (2025) · Biomedicines · doi:10.3390/biomedicines13010229 · Cited by 5
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Patel, S. P., Cano-Linson, E., Chae, Y. K., Schokrpur, S., Lao, C. D., Powers, B., Victor, A. I., Onitilo, A. A., Shin, S., Takebe, N., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00798-1 · Cited by 5
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 6
Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability
Li, R., Lin, Y., Shen, X., Guo, J.-Y., Zhang, Y., Tang, J.-D., Xie, L., & Hu, F.-D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1636122 · Cited by 5
Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
Kudo‐Saito, C., Boku, N., Hirano, H., & Shoji, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009701 · Cited by 5
Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
Sawayama, H., Miyamoto, Y., Ogawa, K., Ohuchi, M., Hisano, Y., Kato, M., Tubakihara, H., Yoshida, N., & Baba, H. (2022) · Surgical Case Reports · doi:10.1186/s40792-022-01580-w · Cited by 5
Prognostic immunogenic characteristics of iron pendant disease modifiers in colon cancer
Wang, X., Meng, Q., Chen, Y., Zhang, Y., Huang, X., Xiang, L., Kong, H., Wang, C., Wang, X., & Zhang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100725 · Cited by 5
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
Karim, F., Amin, A., Liu, M., Vishnuvardhan, N., Amin, S., Shabbir, R., Swed, B., & Khan, U. (2023) · Cancers · doi:10.3390/cancers15164099 · Cited by 5
The potential of monoclonal antibodies for colorectal cancer therapy
Heidari, F., Madadi, S., Alizadeh, N., Alimardani, M. H., Safari, A., Armand, M. H., Pishgahzadeh, E., & Soleimani, M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02151-1 · Cited by 5
Clinical research progress on BRAF V600E-mutant advanced colorectal cancer
Zeng, C., Wang, M., Xie, S., Wang, N., Wang, Z., Yi, D., Kong, F., & Chen, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05301-0 · Cited by 5
Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer
Wang, P., Zhong, W., Huang, Q.-Z., Zhu, Y., Chen, L., & Ye, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01531 · Cited by 5
Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting
Boutin, M., & Gill, S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231162577 · Cited by 5
The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
Ruff, S. M., Shannon, A. H., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15133513 · Cited by 5
CD47 as a potential predictive biomarker in colorectal cancer
Stebbing, J., & Bullock, A. J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011142 · Cited by 5
Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
Doleschal, B., Kirchweger, P., Schwendinger, S., Kupferthaler, A., Burghofer, J., Webersinke, G., Jukic, E., Wundsam, H., Biebl, M., Petzer, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231200462 · Cited by 5
T-reg transcriptomic signatures identify response to check-point inhibitors
Noblejas‐López, M. D. M., García, E. G., Pérez‐Segura, P., Pandiella, A., Győrffy, B., & Ocaña, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-60819-8 · Cited by 4
New approach in Understanding Colorectal Cancer Immunosuppression and Immunotherapy-Based Strategies in the Treatment of Microsatellite Stable Colorectal Cancer
Gulubova, M. V., Chonov, D. C., Ignatova, M., & Yovchev, Y. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0022 · Cited by 4
A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation
Colombo, A., Porretto, C. M., Gebbia, V., Sambataro, D., Scandurra, G., & Valerio, M. R. (2024) · In Vivo · doi:10.21873/invivo.13802 · Cited by 4
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review
Ziogou, A., Giannakodimos, A., Giannakodimos, I., Schizas, D., & Charalampakis, N. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2479410 · Cited by 5
Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan
Huyghe, N. D., Benidovskaya, E., Masoodi, T., Sinapi, I., Cuyper, A. D., Vempalli, F. R., Beyaert, S. P., Bouzin, C., Osorio, F. M., Ferraro, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102201 · Cited by 4
Prognostic importance of CD47 expression on survival of colorectal cancer
Aktepe, O. H., Kurtulan, O., Dama, P. E., Yıldırım, E. Ç., Terzi, A., Kalyoncu, S., Atağ, E., Yavuzşen, T., Üner, M., Karaoğlu, A., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04371-3 · Cited by 4
Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis
Huo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., & Liang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643133 · Cited by 4
Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience
Emiloju, O. E., Foster, N. R., Shah, P., Opneja, A., Gupta, A., Singh, M., Bonneau, K., Steinert, K. O., Saeed, A., Strickler, J. H., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.106022 · Cited by 4
Self-citation
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial
Damato, A., Abate, R. E., Tessitore, S., Frezzetti, D., Maiello, M. R., Righelli, D., Bergamo, F., Antonuzzo, L., Nasti, G., Pietrantonio, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70620-y · Cited by 5
Self-citation
Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives
Fei, J., Cai, C., Wu, W., Shen, H., Han, Y., & Zeng, S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102728 · Cited by 5
Biomarkers for immune checkpoint inhibitors in solid tumors
Kapoor, V., & Kelly, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02942-4 · Cited by 4
Circulating Tumor DNA Testing Overcomes Limitations of Comprehensive Genomic Profiling from Tumor Tissue
Kumar, A., Green, M. F., Thacker, J., Jeck, W. R., & Strickler, J. H. (2023) · Case Reports in Oncology · doi:10.1159/000529813 · Cited by 4
Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions
Dasanu, C. A., AL-ANI, M. S. M., Habibi, S., & Codreanu, I. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231178293 · Cited by 4
Col10A1 is a Potential Immunotherapy Biomarker Associated With Immune Infiltration and Deficient Mismatch Repair in Colon Cancer
Cai, S., Sun, Z., Yan, Y., Li, W., & Wu, Q. (2023) · Immunotherapy · doi:10.2217/imt-2023-0096 · Cited by 4
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023
Mansor, E. A., Mahoney, M., Chénard-Poirier, M., Ramjeesingh, R., Nair, V. J., Kennedy, E. D., Locke, G. E., Welch, S. A., Berry, S. R., Couture, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090593 · Cited by 5
Prognostic and therapeutic insights into colorectal carcinoma through immunogenic cell death gene profiling
Yu, J.-L., Gong, Y., Xu, Z., Chen, L., Li, S., & Cui, Y. (2024) · PeerJ · doi:10.7717/peerj.17629 · Cited by 4
Systemic Therapy Options for Peritoneal Mesothelioma
Tanvetyanon, T., & Simon, G. R. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7031 · Cited by 4
The potential role of PD-1/PD-L1 small molecule inhibitors in colorectal cancer with different mechanisms of action
Kuno, S., Pakpian, N., & Muanprasat, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177351 · Cited by 4
Lights and shadows of microsatellite status characterization in gastrointestinal cancers in the era of cancer precision therapy
Gasparello, J., Piva, V. M., Angerilli, V., Ceccon, C., Sabbadin, M., Luchini, C., Parente, P., Toffolatti, L., Grillo, F., Bergamo, F., et al. (2025) · Pathologica · doi:10.32074/1591-951x-1110 · Cited by 4
Self-citation
Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data
Keil, M., Conrad, T., Becker, M., Keilholz, U., Yaspo, M., Lehrach, H., Schütte, M., Haybaeck, J., & Hoffmann, J. (2021) · Cancers · doi:10.3390/cancers13236018 · Cited by 4
Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis
Amonkar, M. M., Abderhalden, L. A., Frederickson, A. M., Aksomaityte, A., Lang, B. M., Leconte, P., & Zhang, I. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04301-9 · Cited by 4
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1425 · Cited by 5
Gastrointestinal Treatment-Related Adverse Events of Combined Immune Checkpoint Inhibitors: A Meta-Analysis
Karna, R., Deliwala, S. S., Ramgopal, B., Asawa, P., Mishra, R., Mohan, B. P., Jayakrishnan, T., Grover, D., Kalra, T., Bhalla, J. S., et al. (2023) · Immunotherapy · doi:10.2217/imt-2023-0001 · Cited by 4
Microsatellite Instability in Colorectal Cancer: The Evolving Role of Immunotherapy
Desir, A. D., & Ali, F. G. (2023) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000003017 · Cited by 4

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks